We are only able to display limited information for this firm. We display more complete information for all of the following firms:

HOYNG ROKH MONEGIER is the ‘go-to firm for EU regulatory matters in pharma, medical devices, and biotech’, advising across the life cycle of medical products and devices. The practice’s expertise extends to regulatory exclusives, market authorisation and access, and compliance issues, with members of the team also being skilled at handling domestic and cross-border litigation. Team head Liesbeth Weynants ’stands out for her superb knowledge of pharma regulatory law combined with patent litigation expertise’. Tim Robrechts and Ine Letten are noted for their intellectual property expertise, with Letten also being highly knowledgeable of pharmaceutical regulatory law.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘They excel in their advice relating to pharmaceutical regulatory law and are very well connected locally to advise on national legislative changes and decisions.’

  • ‘Liesbeth Weynants stands out for her superb knowledge of pharma regulatory law combined with patent litigation expertise.’

Abbreviated data is displayed for this firm.

Key clients

  • BioNTech
  • Teva
Abbreviated data is displayed for this firm.